New automated insulin delivery system under development

New automated insulin delivery system under development

Three diabetes organisations have joined forces to develop and commercialise an integrated, automated insulin delivery system to improve the lives of people with diabetes. 

Abbott, CamDiab and Ypsomed have announced they are partnering to help lessen the burden of round-the-clock diabetes management for people with the condition.

According to Abbott, the initial focus of the partnership will be in European countries to start with.

The new, integrated automated insulin delivery (AID) system is being designed to connect Abbott’s FreeStyle Libre® 3 sensor to CamDiab’s CamAPS FX mobile app.

The app connects with Ypsomed’s mylifeTM YpsoPump® – creating a smart, automated process to deliver insulin based on real-time glucose data.

The connected, smart wearable solution is designed to continuously monitor a person’s glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing.

Jared Watkin, Senior Vice President of Abbott’s diabetes care business, said: “Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders.

“We want to deliver new, advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”

Roman Hovorka, Director of CamDiab Ltd, said: “Poor glucose control leads to an increased risk of diabetes complications such as blindness, and heart and kidney disease.

“We want to help people with diabetes better manage their glucose through advanced technology.”

He added: “Our CamAPS FX, already approved in Europe, is a highlight adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night.”

Simon Michel, Chief Executive officer of Ypsomed, said: “We are convinced that major challenges of society can only be addressed through partnerships.

“We are therefore proud to expand our partners and connectivity to offer more freedom of choice in managing diabetes.”

He added: “When combined our mylife™ YpsoPump® with the FreeStyle Libre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use.”

The companies intend to complete development by the end of 2022, with commercial availability expected thereafter.

Photo by Utsman Media on Unsplash

Author: Eileen Gilbert